The safety of a low-protein diet in older adults with advanced chronic kidney disease.
Study Goal
The researchers aimed to evaluate the safety of a low-protein diet (LPD) in older adults with advanced chronic kidney disease (CKD).
Results Summary
The study found no significant difference in survival or nutritional status decline for patients prescribed an LPD (≤0.8 g/kg ideal bodyweight or <0.6 g/kg). However, older age (>75 years), lower nutritional status, and higher comorbidity burden showed significant interactions with LPD for mortality and nutritional decline.
Population
Older adults (≥65 years) with advanced CKD (estimated glomerular filtration rate <20 ml/min/1.73 m²) in six European countries.
Effective Dosage
≤0.8 g/kg ideal bodyweight and <0.6 g/kg ideal bodyweight.
Duration
Follow-up through 6 years.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
low-protein diet (LPD) treatment | no change | survival | older adults with advanced CKD | odds ratio [OR] for mortality 1.15 [95% confidence interval (CI) 0.86-1.55] | no difference in survival | #1 |
low-protein diet (LPD) treatment | no change | nutritional status | older adults with advanced CKD | OR for decrease in SGA 1.11 [95% CI 0.74-1.66] | no difference in decrease in nutritional status | #2 |
low-protein diet (LPD) prescribed a LPD <0.6 g/kg ideal bodyweight | no change | survival and nutritional status | patients | - | results were similar | #3 |
low-protein diet (LPD) | neutral | mortality | patients with older age >75 years, lower SGA and higher comorbidity burden | - | significant interaction | #4 |
low-protein diet (LPD) | neutral | nutritional status decline | patients with older age >75 years, lower SGA and higher comorbidity burden | - | significant interaction | #5 |
BACKGROUND: A low-protein diet (LPD) is recommended to patients with advanced chronic kidney disease (CKD), whereas geriatric guidelines recommend a higher amount of protein. The aim of this study was to evaluate the safety of LPD treatment in older adults with advanced CKD. METHODS: The EQUAL study is a prospective, observational study including patients ≥65 years of age with an incident estimated glomerular filtration rate <20 ml/min/1.73 m2 in six European countries with follow-up through 6 years. Nutritional status was assessed by a 7-point subjective global assessment (SGA) every 3-6 months. Prescribed diet (g protein/kg of bodyweight) was recorded on every study visit; measured protein intake was available in three countries. Time to death and decline in nutritional status (SGA decrease of ≥2 points) were analysed using marginal structural models with dynamic inverse probability of treatment and censoring weights. RESULTS: Of 1738 adults (631 prescribed LPD at any point during follow-up), there were 1319 with repeated SGA measurements, of which 267 (20%) decreased in SGA ≥2 points and 565 (32.5%) who died. There was no difference in survival or decrease in nutritional status for patients prescribed a LPD ≤0.8 g/kg ideal bodyweight {odds ratio [OR] for mortality 1.15 [95% confidence interval (CI) 0.86-1.55)] and OR for decrease in SGA 1.11 [95% CI 0.74-1.66]} in the adjusted models. In patients prescribed a LPD <0.6 g/kg ideal bodyweight, the results were similar. There was a significant interaction with LPD and older age >75 years, lower SGA and higher comorbidity burden for both mortality and nutritional status decline. CONCLUSIONS: In older adults with CKD approaching end-stage kidney disease, a traditional LPD prescribed and monitored according to routine clinical practice in Europe appears to be safe.